Switching to aflibercept in patients with neovascular age-related macular degeneration not responding to anti-VEGF treatment: a pilot study [Overstappen op aflibercept bij patiënten die niet reageren op anti-VEGF therapie]

Trial Profile

Switching to aflibercept in patients with neovascular age-related macular degeneration not responding to anti-VEGF treatment: a pilot study [Overstappen op aflibercept bij patiënten die niet reageren op anti-VEGF therapie]

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Nov 2015 Status changed from planning to completed as per Netherlands Trial Register record.
    • 08 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top